Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC

Inclusion Criteria

• •1. 18-80 years of age;
• •2. Patients with stage ⅢB-IV NSCLC are diagnosed by histopathology and cytology;
• •3. Patients' tumor tissues are unresectable as assessed by the investigator;
• •4. Have measurable disease based on RECIST 1.1;
• •5. Driver gene (EGFR/ALK/ROS1) is negative;
• •6. Patients who are receiving first-line platinum-doublet chemotherapy with remaining no fewer than 4 therapeutic cycles;
• •7. Patients in chemotherapy who combined with other systemic therapy (including but not limited to immune checkpoint inhibitors and anti-vascular targeted drugs) are not suitable, but with radiotherapy can be permitted;
• •8. During chemotherapy cycles, patients who take prior treatment with anticancer Chinese medicine less than 4 weeks can be enrolled after stopping medication. If administration time is longer than 4 weeks, at least 4 weeks washout period should be performed;
• •9. Patients are diagnosed with Qi-yin deficiency by the Syndrome Differentiation of Traditional Chinese Medicine;
• •10. The expected survival time ≥3 months;
• •11. The subjects volunteer to sign the informed consent.